A Phase II Multicenter, Double-blind, Randomized, Placebo-Controlled Study of Three Dosages of an Immunomodulator (PGG-Glucan) in High-Risk Surgical Patients

Timothy J. Babineau, MD; Alan Hackford, MD; Andrew Kenler, MD; Bruce Bistrian, MD, PhD; R. Armour Forse, MD, PhD; Patrick G. Fairchild, MD; Stephen Heard, MD; Mark Keroack, MD; Philip Caushaj, MD; Peter Benotti, MD
Arch Surg. 1994;129(11):1204-1210. doi:10.1001/archsurg.1994.01420350102014.
Text Size: A A A
Published online

Objective:  To examine the safety and efficacy of multiple doses of PGG-glucan (poly- [ 1-6]-B-Dglucopyranosyl-[ 1-3]-B-D-glucopyranose) in high-risk patients undergoing major thoracic or abdominal surgery.

Design:  An interventional, multicenter, double-blind, randomized, placebo-controlled study.

Setting:  Four university-affiliated medical centers.

Patients:  Sixty-seven high-risk patients undergoing major thoracic or abdominal surgery.

Intervention:  Patients were randomized in a 1:1:1:1 ratio to receive saline placebo or PGG-glucan at a dose of 0.1 mg/kg, 0.5 mg/kg, and 1.0 mg/kg or 2.0 mg/kg. One dose was administered before surgery and three doses were administered after surgery.

Main Outcome Measures:  To examine the safety and efficacy of PGG-glucan infusion and to identify potentially important factors for a planned phase III study.

Results:  A dose-response trend with regard to infection incidence among patients who received PGG-glucan was observed. Serious infections occurred in four patients who received placebo and in three patients who received PGG-glucan at a dose of 0.1 mg/kg. However, only one patient who received PGG-glucan at a high dose had a serious infection. The incidence and severity of adverse events was comparable in all groups.

Conclusions:  PGG-glucan was generally safe and well tolerated, may decrease postoperative infection rates, and warrants further investigation in a planned phase III trial.(Arch Surg. 1994;129:1204-1210)


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.